Retinal dystrophies are an overlapping group of genetically heterogeneous conditions resulting from mutations in over 250 genes. Here we describe five families affected by an adult-onset retinal dystrophy with early macular involvement and associated central visual loss in the third/fourth decade of life. Affected individuals were found to harbor disease causing variants in DRAM2 (DNA-damage regulated autophagy modulator protein 2). Homozygosity mapping and exome sequencing in a large, consanguineous British family of Pakistani origin revealed a homozygous frameshift variant (c.140delG, p.Gly47Valfs*3) in nine affected family members.
Independently, a gene-based case-control association study was conducted using an exome sequencing dataset of 18 phenotypically similar cases and 1,917 controls. Using a recessive model and a binomial test for rare, presumed biallelic, variants, DRAM2 was found to be the most statistically-enriched gene; one subject was a homozygote (c.362A>T, p.His121Leu) and another a compound heterozygote (c.79T>C, p.Tyr27His and c.217_225del, p.Val73_Tyr75del). DRAM2 encodes a transmembrane lysosomal protein thought to play a role in the initiation of autophagy. Immunohistochemical analysis showed DRAM2 localization to photoreceptor inner segments and to the apical surface of retinal pigment epithelial cells where it may be involved in the process of photoreceptor renewal and recycling to preserve visual function. 4 Retinal dystrophies are a clinically and genetically heterogeneous group of disorders characterized by progressive photoreceptor degeneration. 1 The pattern of visual loss and retinal appearance varies and is related to the degree to which cone and rod photoreceptors are affected. In subjects with retinitis pigmentosa (RP), for example, the rods are affected more severely and earlier than the cones, and the presenting symptoms are typically night blindness and/or visual field loss. Disorders in which the cones are more severely affected than the rods include macular dystrophies (MD; localized loss of central/macular cones as a primary or secondary event) and conerod dystrophies (CRD; central and peripheral cone involvement). MD and CRD show clinical overlap and loss of central vision is often the common presenting symptom.
Frequently, subjects with CRD also report light sensitivity, a symptom which can suggest generalized cone system dysfunction. Assigning a disease category can sometimes be challenging with confounding factors being inter-and intra-familial phenotypic variability and the presence of age-dependent phenotypic transitions. RP, MD and CRD can be transmitted in a dominant, recessive or X-linked manner and, to date, variants in 70, 14 and 30 genes respectively have been shown to give rise to these conditions (RetNet, accessed February 2015).
The initial aim of this study was to identify the genetic basis of an adult-onset retinal dystrophy with early macular involvement ( Figure 1 ) in a consanguineous Pakistani family with multiple affected members living in the UK (family ES1; Figure 2 ).
Affected individuals became symptomatic early in the third decade, describing increasing difficulty with close visual tasks. Neither light sensitivity nor night blindness were significant early symptoms. There was progressive loss of visual acuity in all symptomatic individuals; light sensitivity and difficulty seeing in dim illumination were inconsistent features of advanced disease. Fundus examination revealed maculopathy in all symptomatic individuals tested, with peripheral retinal degeneration being a frequent finding in older subjects. Notably, optical coherence tomography (OCT) imaging in the pre-symptomatic second decade (subject IV.9, family ES1; Figure 2 ) suggested early central photoreceptor cell loss. interval on chromosome 1 (between rs6677953 and rs814987; containing 160 genes) and a 2.9Mb region on chromosome 7 (between rs17140297 and rs12706292; containing 5 genes) ( Figure S1 ). Given the absence of genes previously reported to be associated with retinal dystrophy within these intervals, a whole exome sequencing (WES) strategy was utilized to identify the molecular pathology in the family. DNA from one affected family member (subject IV.6, family ES1; Figure 2 ) was analysed using a HiSeq2000 system (Illumina). After aligning the sequencing data output against the reference genome (hg19/GRCh37) as well as variant calling and filtration steps, a list of 33 homozygous variants was generated (Table S1 ). Only one of these sequence alterations mapped within the shared regions of homozygosity identified in family ES1. This was a homozygous single- S2 ). This missense change was predicted to be pathogenic by a number of bioinformatics prediction tools (Table S3) Meanwhile, interrogation of previously generated WES data from unsolved cases with retinal dystrophy lead to the identification of a homozygous variant in exon 3 of DRAM2 (c.64_66del, p.Ala22del) in a subject of Indian origin. This change, which removes an alanine residue from the first transmembrane domain of the molecule, was predicted to be pathogenic using bioinformatics prediction tools (Table S3) anaemia, which may have been brought on by a vegetarian diet or may be the result of a genetic factor due to parental consanguinity.
Independently, in a study designed to identify novel genes associated with retinal disease, 28 families from the inherited retinal disease clinics at Moorfields Eye Hospital, London were ascertained. Details on this cohort have been previously reported. 3 The main inclusion criteria included a CRD or MD phenotype and an absence of retinal imaging findings suggestive of ABCA4-retinopathy. Genomic DNA from the probands was analyzed by WES and variant filtering was performed as previously described. 3 The molecular diagnosis was identified in 10 of 28 families. 3 On the 18 unsolved cases, a gene based case-control association analysis was performed utilising WES data generated by a consortium of UK based researchers ("UCL-exomes", Table S4 ). Aiming to minimize bias, 4 UCL-exomes controls were initially split into two sets. The first set of 500 randomly selected samples was used in conjunction with EVS to determine variant frequency for inclusion in case control tests. In that context, "rare" variants are variants with MAF<0.5% in EVS and no more than 2 occurrences in this first set of 500 UCL-exomes control samples. The second set of 1,917 unrelated UCL-exomes controls was used to directly compute gene based association p-values, using a recessive disease mode, i.e. samples were labeled as potential carriers only if they carried at least two rare (using the definition stated above) and potentially functional (presumed loss-of-function, nonsynonymous or splice site altering) variants. A binomial test was used for excess of such potential biallelic variants in the 18 cases compared to the 1,917 controls (Table S4) .
The most significant gene-based p-value was obtained for DRAM2 (Table S4) . Two of the 18 cases were found to harbor likely disease-associated variants in this gene.
A 37-year-old female proband (family gc17004, Figure 2 ) of European ancestry was a compound heterozygote for a missense variant (c.79T>C, p.Tyr27His) and an inframe deletion (c.217_225del, p.Val73_Tyr75del). Furthermore, a 47-year-old male proband of South Asian origin (family gc4728, Figure 2 ; parents not knowingly related) was homozygous for a missense change (c.362A>T, p.His121Leu). None of these three changes which are reported to be pathogenic by a number of prediction tools (Table S3 ) exist in dbSNP, EVS or ExAC. Both missense variants, p.Tyr27His Given that affected members of family ES1 are homozygous for a DRAM2 variant that is likely to lead to either nonsense mediated decay of the encoded mRNA, or to a truncated protein of only 47 amino acids, the molecular pathology of the disease is likely to be loss of DRAM2 function. This speculation is further supported by the biallelic state and predicted severity of the additional six likely disease-causing variants identified as well as by the similar phenotype in all five families.
DRAM2, also known as TMEM77 (transmembrane protein 77), encodes a 266 amino acid protein containing six putative transmembrane domains ( Figure 3B ). Previous overexpression studies in HEK293 cells localised it to lysosomal membranes 5, 6 where it initiates the conversion of endogenous LC3-I (microtubule-associated protein light chain 3) to the general autophagosome marker protein, LC3-II (LC3-1/phosphatidylethanolamine conjugate). This suggests that DRAM2 induces the autophagy process. 5 Autophagy is a natural cell survival mechanism triggered in response to stress stimuli such as nutrient starvation or the accumulation of damaged organelles. It is responsible for degrading and recycling cytoplasmic proteins and lipids as well as organelles within the cell. 7 This usually begins with isolation of the macromolecules and organelles within the cytoplasm into single membrane vesicles, which fuse together to produce an autophagosome. These 9 autophagosomes subsequently fuse with lysosomes containing acid hydrolases and form a double-membrane autolysosome. 8, 9 Although the aim of autophagy is to relieve cellular stress, its excessive induction can in some cases lead to apoptosis rather than protection from cell death.
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There is also some evidence to suggest that DRAM2 may have tumour suppressor capability. DRAM2 transcript and protein expression are reduced in ovarian tumours compared to normal matched tissues. 5 Also, siRNA knockdown of endogenous DRAM2 results in reduced conversion to LC3-II in cells subject to starvation-induced autophagy 11 and increased survival in deoxyrubicin treated cells that would normally undergo p53-mediated apoptosis. 5 We note that examination of medical histories in the reported subjects with DRAM2-associated retinal dystrophy provided no evidence of increased susceptibility to cancer.
Although DRAM2 is transcribed ubiquitously (Figure S4 ), 6 in light of the finding that human DRAM2 variants cause retinal dystrophy, we investigated the precise distribution of the normal protein in the mouse retina. Serial sections were taken from mouse eyes at postnatal day 30 and were stained with a goat polyclonal antiserum against DRAM2 (Figure 4 ). Confocal immunofluorescence microscopy showed that DRAM2 localized to the inner segment of the photoreceptor layer and the apical surface of the retinal pigment epithelium (RPE), which are located at the basal and distal ends of the outer segment respectively. This coincides with the primary pathology observed on pre-symptomatic OCT analysis in which the photoreceptor layer appeared specifically affected.
This localization is consistent with a role for DRAM2 in photoreceptor autophagy.
Photoreceptor outer segments are in a constant state of renewal by ciliogenesis in response to light-induced damage. Recent studies have suggested that there is interplay between ciliogenesis and autophagy. In one study it was shown that disruption of ciliogenesis partially inhibited autophagy, while blocking autophagy enhanced primary cilia growth and cilia-associated signaling during normal nutritional conditions. The authors therefore proposed that basal autophagy regulated ciliary growth through the degradation of proteins required for intraflagellar transport. at centriolar satellites located close to the base of the cilium, was rapidly degraded by serum starvation-induced autophagy. This led to ciliary growth, suggesting that OFD1 normally inhibited ciliogenesis. 13 A high level of autophagy is also expected to take place in the RPE. These cells have a key role in processing shed photoreceptor outer segment discs and consequently, in removing toxic metabolites and recycling phototransduction components. This process which involves RPE phagocytosis causes up to 10% photoreceptor volume loss each day and is entrained to the circadian rhythm.
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Indeed there is increasing interest in the role of autophagy in preserving photoreceptor function in connection with the circadian cycle, 16 the aging process 17 and retinal disease pathology. 18 It is therefore likely that the absence of DRAM2 in the retina reduces the efficiency of autophagy in recycling cell components, which in turn reduces photoreceptor renewal, leading to the thin photoreceptor layer observed on OCT which is the first presenting feature in pre-symptomatic patients.
To summarize, we have shown that biallelic missense, nonsense and frameshift variants in DRAM2 cause retinal dystrophy with early macular cone photoreceptor involvement. The clinical features and course of retinal degeneration were highly similar among affected individuals from the five reported families. Our findings suggest that DRAM2 is essential for photoreceptor survival and further studies are expected to provide important insights into its precise role in the retina. 
Web Resources
The URLs for data presented herein are as follows: A respectively represent the 1% and 10% most deleterious changes predicted in the human genome. 18 probands with (i) a retinal dystrophy with early cone photoreceptor involvement (macular dystrophy or cone rod dystrophy), (ii) absence of fundoscopic and fundus autofluorescence imaging features suggestive of ABCA4-retinopathy and (iii) an unknown molecular diagnosis after inspection of exome sequencing data for causal variants in known retinal dystrophy genes. The exomes from all cases were prepared using the Agilent SureSelectXT Human All Exon V5 capture and an Illumina HiSeq2000 sequencer.
**UCL-exomes control samples: 1,917 unrelated individuals, predominantly of European origin, with no diagnosis of retinal disease. Exome sequencing data from controls was analyzed using the same sequence variant-calling strategy as the cases. Variants with a read depth <7 were ignored.
We considered a case, or a control, as a "recessive disease candidate" if it harboured -of-function, nonsynonymous or splice site altering) rare variants in the heterozygous state ("likely the homozygous state ("likely homozygotes"). As "rare" we defined changes that: (i) had a minor allele frequency of <0.5% in the EVS dataset and (ii) had <2 occurrences in 500 additional UCL-exomes control samples; the latter were randomly sampled and not included directly in the case-control analysis. The BAM files were inspected using the Integrative Genomics Viewer (IGV) and obvious artefacts were removed. This IGV check also excluded pairs of genetic variants located on the same haplotype, when evidenced by the presence of both variants on the same short sequencing reads.
For each gene, the number of 'recessive disease candidates' was determined in the case and control groups. To remove false homozygous calls that might result from low sequencing depth, we excluded variants with a read depth of 6 or less. Autosomal genes were then ranked based on a binomial p value test. This test computes the exact probability of seeing the observed number, or more, of 'recessive disease candidates' in cases under the assumption that the prevalence in cases was equal to that in controls, using the binomial distribution. This binomial test required a sample size estimate in cases and controls, which varied between genes owing to variable coverage. To estimate these two numbers for each gene, we listed all polymorphic coding positions within that gene and we computed the average of non-missing calls. This average was the number that was used in the binomial test.
